{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274319","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.247811+00:00","generated_at":"2026-05-16T22:29:01.198044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mereo BioPharma Q3 2025 net loss narrows to $7.0M; cash $48.7M; setrusumab data expected year-end","bullets":["Net loss of $7.0M in Q3 2025 vs $15.0M in Q3 2024; operating loss of $10.0M.","Cash and cash equivalents $48.7M as of Sep 30, 2025 (down from $69.8M Dec 31, 2024).","R&D expenses rose to $4.3M (up $1.1M YoY) driven by setrusumab manufacturing and alvelestat Phase 3 prep.","Phase 3 Orbit (p<0.039) and Cosmic (p<0.05) data for setrusumab in OI expected around end of 2025.","Partnering discussions for alvelestat ongoing; vantictumab license to āshibio with retained EU rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274319","json":"https://secwatch.observer/filing/0001193125-25-274319.json","markdown":"https://secwatch.observer/filing/0001193125-25-274319.md","text":"https://secwatch.observer/filing/0001193125-25-274319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/0001193125-25-274319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312525274319/mreo-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:29:01.198044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}